Limits...
A Multicenter, Single-Blind Randomized, Controlled Study of a Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Patient-Reported Outcomes at 2 Years.

Few J, Cox SE, Paradkar-Mitragotri D, Murphy DK - Aesthet Surg J (2015)

Bottom Line: The effectiveness of Juvéderm Voluma XC was examined from the patient perspective.Increased satisfaction with outer and lower cheek areas and cheek-bone projection and clinically significant improvements in LAFM were noted through month 24.Juvéderm Voluma XC for age-related MVD is effective and well-tolerated from the patient perspective, with results lasting up to 2 years. 4 Therapeutic.

View Article: PubMed Central - PubMed

Affiliation: Dr Few is Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois. Dr Cox is Assistant Clinical Professor, University of North Carolina, Chapel Hill, North Carolina; and is Supervising Physician, Dermatology Program, Duke University, Durham, North Carolina. Dr Paradkar-Mitragotri was the Manager of Biostatistics at the time of this study and is a former employee of Allergan, Inc., Irvine, California, and Ms Murphy is the Director of Clinical Development Submissions at Allergan, Inc., Irvine, California.

No MeSH data available.


Related in: MedlinePlus

Percentage of patients who rated themselves as improved or much improved on the Global Aesthetic Improvement Scale.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4482214&req=5

SJV050F2: Percentage of patients who rated themselves as improved or much improved on the Global Aesthetic Improvement Scale.

Mentions: Not all patients completed all outcome measurements at all visits; thus patient numbers vary between assessments. Six months after treatment, 92.8% of patients rated their midface volume as improved or much improved on the GAIS; a majority (79.0%) of patients still provided these ratings at 2 years (Figure 2). Overall satisfaction with facial appearance scores improved from baseline in 89.8% of patients at 6 months and in 75.8% of patients at 2 years (Figure 3). At all time points, increases from baseline in mean scores were statistically significant. The percentage of patients with improved satisfaction with facial appearance at month 6 was high across all injection volumes but increased with greater injection volumes. By injection volume quartile (initial plus touch-up volume), the percentage of patients with improved satisfaction was 78.4% for ≤4.6 mL, 89.8% for 4.6 to ≤6.5 mL, 94.3% for 6.5 to ≤8.9 mL, and 96.2% for >8.9 mL.Figure 2.


A Multicenter, Single-Blind Randomized, Controlled Study of a Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Patient-Reported Outcomes at 2 Years.

Few J, Cox SE, Paradkar-Mitragotri D, Murphy DK - Aesthet Surg J (2015)

Percentage of patients who rated themselves as improved or much improved on the Global Aesthetic Improvement Scale.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4482214&req=5

SJV050F2: Percentage of patients who rated themselves as improved or much improved on the Global Aesthetic Improvement Scale.
Mentions: Not all patients completed all outcome measurements at all visits; thus patient numbers vary between assessments. Six months after treatment, 92.8% of patients rated their midface volume as improved or much improved on the GAIS; a majority (79.0%) of patients still provided these ratings at 2 years (Figure 2). Overall satisfaction with facial appearance scores improved from baseline in 89.8% of patients at 6 months and in 75.8% of patients at 2 years (Figure 3). At all time points, increases from baseline in mean scores were statistically significant. The percentage of patients with improved satisfaction with facial appearance at month 6 was high across all injection volumes but increased with greater injection volumes. By injection volume quartile (initial plus touch-up volume), the percentage of patients with improved satisfaction was 78.4% for ≤4.6 mL, 89.8% for 4.6 to ≤6.5 mL, 94.3% for 6.5 to ≤8.9 mL, and 96.2% for >8.9 mL.Figure 2.

Bottom Line: The effectiveness of Juvéderm Voluma XC was examined from the patient perspective.Increased satisfaction with outer and lower cheek areas and cheek-bone projection and clinically significant improvements in LAFM were noted through month 24.Juvéderm Voluma XC for age-related MVD is effective and well-tolerated from the patient perspective, with results lasting up to 2 years. 4 Therapeutic.

View Article: PubMed Central - PubMed

Affiliation: Dr Few is Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois. Dr Cox is Assistant Clinical Professor, University of North Carolina, Chapel Hill, North Carolina; and is Supervising Physician, Dermatology Program, Duke University, Durham, North Carolina. Dr Paradkar-Mitragotri was the Manager of Biostatistics at the time of this study and is a former employee of Allergan, Inc., Irvine, California, and Ms Murphy is the Director of Clinical Development Submissions at Allergan, Inc., Irvine, California.

No MeSH data available.


Related in: MedlinePlus